Skip to main content

Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Exceed 52-Week High

Shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) traded today at $152.16, eclipsing its 52-week high. Approximately 960,000 shares have changed hands today, as compared to an average 30-day volume of 680,000 shares.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is currently priced 11.9% above its average consensus analyst price target of $133.93.

In the past 52 weeks, Biohaven Pharmaceutical Holding Company Ltd. share prices are bracketed by a low of $79.01 and a high of $152.16 and is now at $152.03, 92% above that low price.

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.